Related Experiment Video
Updated: Aug 15, 2026
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Clinical, pathological and molecular features of the chronic myeloproliferative disorders: MPD 2005 and beyond
1Department of Hematology, University Hospital Antwerp, Belgium.
Abstract:
The combined use of bone marrow histopathology, biomarkers and clinical features has the potential to diagnose, stage and distinguish early and overt stages of ET, PV and idiopathic myelofibrosis, that has an important impact on prognosis and treatment of MPD patients. As the extension of the PVSG and WHO for ET, PV and agnogenic myeloid metaplasia (AMM), a new set of European clinical and pathological (ECP) criteria clearly distinct true ET from early or latent PV mimicking true ET, overt and advanced polycythemia vera (PV), and from thrombocythemia associated with prefibotic, early fibrotic stages of chronic megakaryocytic granulocytic metaplasia (CMGM) or chronic idiopathic myelofibrosis (CIMF). Cases of atypical MPD and masked PV are usually overlooked by clinicians and pathologists. Bone marrow biopsy will not differentiate between post-PV myelofibrosis versus so-called classical agnogenic myeloid metaplasia. The recent discovery of the JAK2 V617F mutation can readily explain the trilinear megakaryocytic, erythroid and granulocytic proliferation in the bone marrow, but also the etiology of the platelet-mediated microvascular thrombotic complications at increased platelet counts and red cell mass in essential thrombocythemia and polycythemia vera.
Insights
Diagnosing myeloproliferative neoplasms (MPNs) like essential thrombocythemia (ET) and polycythemia vera (PV) is improved by combining bone marrow pathology, biomarkers, and clinical data. New European criteria aid in distinguishing MPN subtypes and understanding disease progression.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and idiopathic myelofibrosis, present diagnostic challenges.
- Accurate differentiation of early and overt stages of these MPNs is crucial for prognosis and treatment planning.
- Existing diagnostic criteria may overlook atypical presentations and mask conditions like polycythemia vera.
Purpose of the Study:
- To evaluate the combined utility of bone marrow histopathology, biomarkers, and clinical features for diagnosing and staging MPNs.
- To introduce and assess new European clinical and pathological (ECP) criteria for distinguishing true ET from early PV and other myelofibrotic conditions.
- To clarify the diagnostic limitations of bone marrow biopsy in differentiating post-PV myelofibrosis from classical agnogenic myeloid metaplasia.
Main Methods:
- Integration of bone marrow histopathology findings.
- Analysis of relevant biomarkers, including the JAK2 V617F mutation.
- Application of established and novel European clinical and pathological (ECP) criteria.
- Clinical feature assessment for staging and differentiation.
Main Results:
- The combined approach offers potential for accurate diagnosis, staging, and differentiation of ET, PV, and myelofibrosis.
- ECP criteria effectively distinguish true ET from early or latent PV and myelofibrotic conditions.
- The JAK2 V617F mutation provides insight into the molecular basis of trilinear proliferation and thrombotic complications in ET and PV.
Conclusions:
- A multifaceted diagnostic strategy incorporating histopathology, biomarkers, and clinical data significantly enhances MPN management.
- The developed ECP criteria represent a valuable tool for precise classification of MPNs, improving patient stratification.
- Understanding the role of JAK2 V617F mutation is key to unraveling the pathophysiology and thrombotic risks associated with ET and PV.
Related Concept Videos
01:15Differentiation of Common Myeloid Progenitor Cells
01:24Parkinson Disease ll: Pathophysiology